These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35838021)

  • 1. Acute radiation syndrome drug discovery using organ-on-chip platforms.
    Singh VK; Seed TM
    Expert Opin Drug Discov; 2022 Aug; 17(8):865-878. PubMed ID: 35838021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models for acute radiation syndrome drug discovery.
    Singh VK; Newman VL; Berg AN; MacVittie TJ
    Expert Opin Drug Discov; 2015 May; 10(5):497-517. PubMed ID: 25819367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonhuman primates as models for the discovery and development of radiation countermeasures.
    Singh VK; Olabisi AO
    Expert Opin Drug Discov; 2017 Jul; 12(7):695-709. PubMed ID: 28441902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of amifostine for the acute radiation syndrome.
    Singh VK; Seed TM
    Expert Opin Drug Saf; 2019 Nov; 18(11):1077-1090. PubMed ID: 31526195
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent advances in medical countermeasure development against acute radiation exposure based on the US FDA animal rule.
    MacVittie TJ; Farese AM
    J Radiol Prot; 2021 Nov; 41(4):. PubMed ID: 34433144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation countermeasure agents: an update (2011-2014).
    Singh VK; Newman VL; Romaine PL; Wise SY; Seed TM
    Expert Opin Ther Pat; 2014 Nov; 24(11):1229-55. PubMed ID: 25315070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure.
    Singh VK; Seed TM
    Expert Opin Investig Drugs; 2020 May; 29(5):429-441. PubMed ID: 32450051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of biomarkers for assessing radiation injury and efficacy of countermeasures.
    Singh VK; Newman VL; Romaine PL; Hauer-Jensen M; Pollard HB
    Expert Rev Mol Diagn; 2016; 16(1):65-81. PubMed ID: 26568096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug discovery strategies for acute radiation syndrome.
    Singh VK; Seed TM; Olabisi AO
    Expert Opin Drug Discov; 2019 Jul; 14(7):701-715. PubMed ID: 31008662
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of gamma-tocotrienol as a radiation medical countermeasure for the acute radiation syndrome: current status and future perspectives.
    Singh VK; Seed TM
    Expert Opin Investig Drugs; 2023 Jan; 32(1):25-35. PubMed ID: 36655861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological studies of nonhuman primates exposed to supralethal doses of total- or partial-body radiation: influence of a medical countermeasure, gamma-tocotrienol.
    Singh VK; Wise SY; Fatanmi OO; Petrus SA; Carpenter AD; Lee SH; Hauer-Jensen M; Seed TM
    Sci Rep; 2024 Mar; 14(1):5757. PubMed ID: 38459144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents.
    Singh VK; Romaine PL; Newman VL; Seed TM
    Expert Opin Ther Pat; 2016 Dec; 26(12):1399-1408. PubMed ID: 27610458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where are the medical countermeasures against the ARS and DEARE? A current topic relative to an animal model research platform, radiation exposure context, the acute and delayed effects of acute exposure, and the FDA animal rule.
    MacVittie TJ
    Int J Radiat Biol; 2023; 99(7):994-1008. PubMed ID: 36811500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.
    Singh VK; Seed TM
    Int J Radiat Biol; 2017 Sep; 93(9):851-869. PubMed ID: 28650707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Drug Products for the Treatment of Acute Radiation Syndrome.
    Libero M
    Disaster Med Public Health Prep; 2024 Jan; 17():e571. PubMed ID: 38163973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status.
    Singh VK; Garcia M; Seed TM
    Int J Radiat Biol; 2017 Sep; 93(9):870-884. PubMed ID: 28657406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond.
    Singh VK; Seed TM
    Int J Radiat Biol; 2021; 97(11):1526-1547. PubMed ID: 34402734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing polyphenolic acetates as radiation countermeasure agents: current status and future perspectives.
    Venkateswaran K; Shrivastava A; Prasad AK; Parmar VS; Dwarakanath BS
    Drug Discov Today; 2020 Apr; 25(4):781-786. PubMed ID: 32062010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on romiplostim for treatment of acute radiation syndrome.
    Singh VK; Seed TM
    Drugs Today (Barc); 2022 Mar; 58(3):133-145. PubMed ID: 35274632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with 'standard of care' medicinal and procedures not requiring regulatory approval for use.
    Singh VK; Hanlon BK; Santiago PT; Seed TM
    Int J Radiat Biol; 2017 Sep; 93(9):885-906. PubMed ID: 28657400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.